- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
27 result(s) found for: Bacterial Infections AND Infectious Disease AND Placebo.
Displaying page 1 of 2.
| EudraCT Number: 2012-000938-19 | Sponsor Protocol Number: 4PH/2012/002 | Start Date*: 2012-06-11 | |||||||||||
| Sponsor Name:NOVINTETHICAL PHARMA SAGL | |||||||||||||
| Full Title: Safety and Efficacy of tablets containing extract of Hibiscus Sabdariffa (HS) and Propoli versus placebo in the treatment of the cystitis with Ciproxin | |||||||||||||
| Medical condition: patients with diagnosys of cystitis confirmed by urine culture | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-002644-40 | Sponsor Protocol Number: B3451002 | Start Date*: 2015-05-27 | ||||||||||||||||
| Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | ||||||||||||||||||
| Full Title: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Staphylococcus Aureus 4-Antigen Vaccine (SA4Ag) in Adults Undergoing Elective Posterior Instrum... | ||||||||||||||||||
| Medical condition: Prophylaxis for prevention of Post-operative S. aureus infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) HU (Completed) AT (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-000476-34 | Sponsor Protocol Number: V59_40 | Start Date*: 2011-06-08 | ||||||||||||||||
| Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. | ||||||||||||||||||
| Full Title: A Phase IV,PlaceboControlled,Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix) and Quadrivale... | ||||||||||||||||||
| Medical condition: Menveo is indicated for active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2014-001759-22 | Sponsor Protocol Number: PGX401-11 | Start Date*: 2015-07-24 | |||||||||||||||||||||||||||||||
| Sponsor Name:Laboratoire Innotech International | |||||||||||||||||||||||||||||||||
| Full Title: Assessment of the efficacy of POLYGYNAX® in the empirical treatment of infectious vaginitis International, multicentre, randomised, double-blind, parallel group study, comparative versus miconazole | |||||||||||||||||||||||||||||||||
| Medical condition: Patients presenting with abnormal vaginal discharge associated with other vaginal symptoms (i.e. vaginal burning and/or vaginal irritation and/or vaginal pain) clinically evoking infectious vaginit... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) CZ (Completed) SK (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-005187-25 | Sponsor Protocol Number: BUC-SI-11-001 | Start Date*: 2012-05-31 | |||||||||||
| Sponsor Name:SOCIETA' LABORATORIO FARMACEUTICO S.I.T. SRL | |||||||||||||
| Full Title: Efficacy and tolerability clinical trial of an immunostimulant made from inactivated bacteria (BUCCALIN) in the prophylaxis of infection of the airways (rhinotracheobronchitis, colds). Double-blind... | |||||||||||||
| Medical condition: Episodes classified by upper respiratory infections (otitis, tonsillitis, sinusitis, pharyngotonsillitis, nasopharyngitis) and lower respiratory tract (bronchitis, pneumonia). | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-007055-28 | Sponsor Protocol Number: P-080623-01 | Start Date*: 2009-06-04 | |||||||||||
| Sponsor Name:Ferrer International, SA | |||||||||||||
| Full Title: GF-001001-00 cream. A multicentre, randomised, double-blind, parallel, placebo-controlled phase II study to assess the efficacy and safety of 3 different doses of GF-001001-00 cream versus placebo... | |||||||||||||
| Medical condition: Secondarily-infected traumatic lesions | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) ES (Completed) CZ (Completed) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004420-29 | Sponsor Protocol Number: 205213 | Start Date*: 2016-12-14 | |||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
| Full Title: A Phase 2, Open-label, Controlled, Multi-Center Extension Study to Evaluate 4-Year Antibody Persistence and Booster Response Fol-lowing MenABCWY Vaccination in Healthy Adolescents and Young Adults ... | |||||||||||||
| Medical condition: Healthy volunteers (Immunisation against meningococcal infections) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003835-28 | Sponsor Protocol Number: APHP210089 | Start Date*: 2022-02-17 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS | |||||||||||||
| Full Title: Prevention of C. difficile infections with oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a double-blind, randomized, placebo-controlled trial ” VANCALLO | |||||||||||||
| Medical condition: Patients hospitalized for an allogeneic hematopoietic stem cell transplant | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004842-27 | Sponsor Protocol Number: Repha_1398 | Start Date*: 2018-07-17 | ||||||||||||||||
| Sponsor Name:Repha GmbH | ||||||||||||||||||
| Full Title: Clinical Trial to investigate the efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in the prophylaxis of catheter associated urinary tract infections | ||||||||||||||||||
| Medical condition: Prophylaxis of catheter-associated chronically inflammatory recurring urinary tract infections in adult patients | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2009-015198-11 | Sponsor Protocol Number: B1971014(6108A1-3003) | Start Date*: 2011-07-01 | |||||||||||
| Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: A Phase 3, Randomized, Active-Controlled, Observer-Blinded Trial to Assess the Safety and Tolerability of a Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rLP2086) Vaccine Given in Hea... | |||||||||||||
| Medical condition: Bacterial Meningitis | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) CZ (Completed) LT (Completed) EE (Completed) FI (Completed) DK (Completed) ES (Completed) DE (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-002980-17 | Sponsor Protocol Number: BV-2005/01 PRIMES | Start Date*: 2007-07-12 | |||||||||||
| Sponsor Name:OM PHARMA | |||||||||||||
| Full Title: Double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® in children suffering from recurrent upper respiratory tract infections | |||||||||||||
| Medical condition: Recurrent upper respiratory tract infections in children | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) BE (Completed) CZ (Completed) AT (Completed) IT (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-004594-82 | Sponsor Protocol Number: CSU11001 | Start Date*: 2012-01-17 | ||||||||||||||||
| Sponsor Name:Schur Pharmazeutika GmbH & Co. KG | ||||||||||||||||||
| Full Title: Efficacy of an intravesical instillation with neomycin solution in acute cystitis: a double-blind, placebo-controlled trial in patients with permanent intravesical catheter | ||||||||||||||||||
| Medical condition: Treatment of urinary tract infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BG (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2015-002994-39 | Sponsor Protocol Number: Cx611-0204 | Start Date*: 2016-04-06 |
| Sponsor Name:TIGENIX, S.A.U. | ||
| Full Title: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for... | ||
| Medical condition: Severe community-acquired bacterial pneumonia requiring mechanical ventilation and/or vasopressors. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) BE (Completed) LT (Completed) GB (Completed) FR (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-005736-17 | Sponsor Protocol Number: NL56697.041.16 | Start Date*: 2016-09-20 | ||||||||||||||||||||||||||
| Sponsor Name:University Medical Center Utrecht | ||||||||||||||||||||||||||||
| Full Title: Prevention of severe infectious complications after colorectal surgery using antimicrobial decontamination of the digestive tract (PreCaution trial) | ||||||||||||||||||||||||||||
| Medical condition: The medical condition under investigation: surgical site infections (bacterial) after elective colorectal surgery. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2011-000653-23 | Sponsor Protocol Number: TMC207-TiDP13-C210 | Start Date*: 2012-06-13 | |||||||||||
| Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
| Full Title: A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Myc... | |||||||||||||
| Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Prematurely Ended) LV (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004657-24 | Sponsor Protocol Number: 7985 | Start Date*: 2014-10-24 | |||||||||||
| Sponsor Name:Southampton University | |||||||||||||
| Full Title: A randomised, double-blind, placebo controlled, feasibility study exploring the role of Chinese herbal medicine in the treatment of women with recurrent urinary tract infections. | |||||||||||||
| Medical condition: Recurrent urinary tract infections | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002608-29 | Sponsor Protocol Number: CS2514-2017-0003 | Start Date*: 2017-12-12 | ||||||||||||||||
| Sponsor Name:Entasis Therapeutics | ||||||||||||||||||
| Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infe... | ||||||||||||||||||
| Medical condition: Complicated Urinary Tract Infection including Acute Pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BG (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-015953-18 | Sponsor Protocol Number: DORIPED3002 | Start Date*: 2010-05-28 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
| Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infec... | |||||||||||||
| Medical condition: Complicated Urinary Tract Infections | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Prematurely Ended) CZ (Completed) PL (Temporarily Halted) LV (Prematurely Ended) DE (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000344-10 | Sponsor Protocol Number: | Start Date*: 2012-05-24 | |||||||||||||||||||||||||||||||
| Sponsor Name:Medical Research Council [...] | |||||||||||||||||||||||||||||||||
| Full Title: Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a randomised controlled trial | |||||||||||||||||||||||||||||||||
| Medical condition: S. aureus bacteraemia | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-002491-14 | Sponsor Protocol Number: Sepsis_IFNg | Start Date*: 2012-11-08 | |||||||||||||||||||||||||||||||
| Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||||||||||||||||||||||
| Full Title: The effects of interferon-gamma on sepsis-induced immunoparalysis, a randomised double-blind placebo-controlled pilot (Phase IIIb) study | |||||||||||||||||||||||||||||||||
| Medical condition: Sepsis-induced immunoparalysis (SIRS, Sepsis, Septic shock) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.